|
|
Taiwan Academic Institutional Repository >
Browse by Author
|
"hsu c"
Showing items 6-30 of 881 (36 Page(s) Totally)
1 2 3 4 5 6 7 8 9 10 > >>
View [10|25|50] records per page
| 國家衛生研究院 |
2024-10 |
TCOG T3221 study: The registry of genetic alterations of Taiwan biliary tract cancer
|
Chiang, N;Hsu, C;Chen, J;Dai, M;Bai, L;Yen, C;Wang, T;Hsieh, Y;Lin, J;Chiu, T;Cheng, H;Yang, Y;Hsiao, C;Chen, L;Chen, M |
| 國家衛生研究院 |
2024-08-06 |
Pan-Asian adapted ESMO clinical practice guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer
|
Chen, LT;Vogel, A;Hsu, C;Chen, MH;Fang, W;Pangarsa, EA;Sharma, A;Ikeda, M;Park, JO;Tan, CK;Regala, E;Tai, D;Tanasanvimon, S;Charoentum, C;Chee, CE;Lui, A;Sow, J;Oh, DY;Ueno, M;Ramaswamy, A;Jeo, WS;Zhou, J;Curigliano, G;Yoshino, T;Bai, LY;Pentheroudakis, G;Chiang, NJ;Cervantes, A;Chen, JS;Ducreux, M |
| 國家衛生研究院 |
2024-06-21 |
A phase 1 study of biweekly nab-paclitaxel/oxaliplatin/S-1/LV for advanced upper gastrointestinal cancers: TCOG T1216 study
|
Tsai, HJ;Yang, SH;Hsiao, CF;Kao, HF;Su, YY;Shan, YS;Yen, CJ;Du, JS;Hsu, C;Wu, IC;Chen, LT |
| 國家衛生研究院 |
2023-11 |
Nivolumab plus ipilimumab (N plus I) for potentially resectable hepatocellular carcinoma (HCC): Efficacy and surgical outcome
|
Su, YY;Lin, YJ;Hsiao, CF;Ou, DL;Chen, SC;Wang, HW;Wang, JH;Wu, YM;Lee, WC;Chou, SC;Ho, CL;Chiu, CF;Chen, LT;Shen, YS;Cheng, AL;Hsu, C |
| 國家衛生研究院 |
2023-06 |
Aristolochic acid (AA) exposure and telomere maintenance mechanism in liver angiosarcoma (AS)
|
Chen, TWW;Hsu, CL;Wu, YC;Ou, DL;Su, YY;Cheng, AL;Hsu, C |
| 國家衛生研究院 |
2023-06 |
Atezolizumab plus bevacizumab for patients with unresectable hepatocellular carcinoma and high hepatitis B viral load: Focusing on hepatic safety and viral kinetics
|
Chen, SC;Tsou, HHS;Lee, TY;Wang, HW;Chen, YH;Wang, TE;Su, YY;Yang, S;Chiu, CF;Liu, TW;Cheng, AL;Chen, LT;Hsu, C |
| 國立成功大學 |
2023 |
Combination of GT90001 and nivolumab in patients with advanced hepatocellular carcinoma: a multicenter, single-arm, phase 1b/2 study
|
Hsu, C.;Chang, Y.-F.;Yen, C.-J.;Xu, Y.-W.;Dong, M.;Tong, Y.-Z. |
| 國立成功大學 |
2023 |
Evaluation of combination treatment with DS-1205c, an AXL kinase inhibitor, and osimertinib in metastatic or unresectable EGFR-mutant non-small cell lung cancer: results from a multicenter, open-label phase 1 study
|
Yang, J.C.-H.;Su, W.-C.;Chiu, Chiu C.-H.;Shiah, H.-S.;Lee, K.-Y.;Hsia, T.-C.;Uno, M.;Crawford, N.;Terakawa, H.;Chen, W.-C.;Takayama, G.;Hsu, C.;Hong, Y.;Saintilien, C.;McGill, J.;Chang, G.-C. |
| 臺大學術典藏 |
2022-09-15T01:09:59Z |
A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil
|
Hsu C.-H.; Cheng A.-L.; Hsu C.; Yang C.-H.; Lu Y.-S.; Chia-Chi Lin; Bu C.-F.; Yeh K.-H. |
| 臺大學術典藏 |
2022-09-15T01:09:55Z |
A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with chemotherapy-pretreated metastatic breast cancer
|
Chia-Chi Lin; Cheng A.-L.; Hsu C.-H.; Lu Y.-S.; Hsu C.; Yeh K.-H.; Wu C.-Y.; Huang C.-S.; Yang C.-H. |
| 臺大學術典藏 |
2022-09-15T01:09:54Z |
Arsenic trioxide in patients with hepatocellular carcinoma: A phase II trial
|
Chia-Chi Lin; Hsu C.; Hsu C.-H.; Hsu W.-L.; Cheng A.-L.; Yang C.-H. |
| 臺大學術典藏 |
2022-09-15T01:09:53Z |
Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma
|
Chia-Chi Lin; Yeh K.-H.; Yang C.-H.; Hsu C.; Tsai Y.-C.; Hsu W.-L.; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2022-09-15T01:09:52Z |
Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment
|
Lin Z.-Z.; Hsu C.; Chang Y.-C.; Yu C.-J.; Hsu C.-H.; Chia-Chi Lin; Cheng A.-L.; Yang P.-C.; Yang C.-H. |
| 臺大學術典藏 |
2022-09-15T01:08:51Z |
Safety and Preliminary Efficacy of Ramucirumab in Combination with FOLFOX4 in Patients with Advanced Hepatocellular Carcinoma: A Nonrandomized, Open-Label, Phase Ib Study
|
Chia-Chi Lin; Yang T.-S.; Yen C.-J.; Cheng R.; Liu J.; Hsu C. |
| 臺大學術典藏 |
2022-09-14T01:29:27Z |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Shao Y.-Y.; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Tseng J.-H.; Ho M.-C.; Lee R.-C.; Liang P.-C.; Liao L.-Y.; Huang K.-W.; Hu J.-T.; Liang J.-D.; Kee K.-M.; Lin C.-L.; Wang C.-K.; Lu S.-N.; Wang J.-H.; Lee W.-C.; CHIEN-HUNG CHEN; Liu C.-J.; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; Hsu C.; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group |
| 臺大學術典藏 |
2022-09-14T01:29:23Z |
Limited predictive or prognostic role of tumor-infiltrating tissue-resident memory cd8 t cells in patients with hepatocellular carcinoma receiving immunotherapy
|
Shen Y.-C.; Yeh C.-P.; Jeng Y.-M.; Hsu C.; Hsu C.-H.; Lin Z.-Z.; Shao Y.-Y.; Lu L.-C.; Liu T.-H.; CHIEN-HUNG CHEN; Cheng A.-L. |
| 臺大學術典藏 |
2022-09-06T02:56:06Z |
Comparison of GATK and DeepVariant by trio sequencing
|
Lin Y.-L.; Chang P.-C.; Hsu C.; Hung M.-Z.; YIN-HSIU CHIEN; Hwu W.-L.; Lai F.P.; Lee N.-C. |
| 國家衛生研究院 |
2022-09 |
Systemic treatment of advanced unresectable hepatocellular carcinoma after first-line therapy: Expert recommendations from Hong Kong, Singapore, and Taiwan
|
Yau, T;Tai, D;Chan, SL;Huang, YH;Choo, SP;Hsu, C;Cheung, TT;Lin, SM;Yong, WP;Lee, J;Leung, T;Shum, T;Yeung, CSY;Tai, AY;Law, ALY;Cheng, AL;Chen, LT |
| 臺大學術典藏 |
2022-08-23T02:35:00Z |
Case Report: Maintenance Nivolumab in Complete Responder After Multimodality Therapy in Metastatic Pancreatic Adenocarcinoma
|
Bai L.-Y.; Hsu C.; Yang S.-H.; Lee J.-C.; Chen B.-B.; SUNG-HSIN KUO |
| 臺大學術典藏 |
2022-08-19T06:48:42Z |
AXL and MET in Hepatocellular Carcinoma: A Systematic Literature Review
|
Hsu C.; Huang Y.-H.; Lin S.-M.; CHIH-HUNG HSU |
| 臺大學術典藏 |
2022-08-19T06:48:40Z |
Association of annexin A10 expression with poor prognosis of intrahepatic cholangiocarcinoma
|
Shao Y.-Y.; Kuo H.-Y.; Jeng Y.-M.; Wu Y.-M.; Wang H.-P.; Hsu C.; CHIH-HUNG HSU; Hsu H.-C.; Cheng A.-L.; Lin Z.-Z. |
| 臺大學術典藏 |
2022-08-12T06:28:23Z |
Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-na?ve patients with locally advanced or metastatic breast carcinoma
|
Hsu C.; Huang C.-S.; Chao T.-Y.; Lu Y.-S.; Bu C.-F.; Chen M.M.; KING-JEN CHANG; Cheng A.-L. |
| 臺大學術典藏 |
2022-08-12T06:27:55Z |
Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin
|
Shao Y.-Y.; Kuo K.-T.; Hu F.-C.; Lu Y.-S.; Huang C.-S.; Liau J.-Y.; Lee W.-C.; Hsu C.; Kuo W.-H.; KING-JEN CHANG; Lin C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2022-07-26T08:55:57Z |
Association of annexin A10 expression with poor prognosis of intrahepatic cholangiocarcinoma
|
Shao Y.-Y.; Kuo H.-Y.; YUNG-MING JENG; Wu Y.-M.; Wang H.-P.; Hsu C.; Hsu C.-H.; Hsu H.-C.; Cheng A.-L.; Lin Z.-Z. |
| 國家衛生研究院 |
2022-07 |
Potential roles of gut microbiome in patients with hepatocellular carcinoma treated with immune checkpoint inhibitors
|
Su, YY;Lee, WH;Wang, JH;Wang, HW;Chen, TW;Chen, BB;Ho, HJ;Liu, TH;Chou, SC;Chen, BR;Liu, TW;Chen, LT;Wu, CY;Hsu, C |
Showing items 6-30 of 881 (36 Page(s) Totally)
1 2 3 4 5 6 7 8 9 10 > >>
View [10|25|50] records per page
|
